Clinical characteristics in HBsAg+ and HBsAg− DLBCL patients
| . | HBsAg+ DLBCL . | HBsAg− DLBCL . | P* . |
|---|---|---|---|
| No. of patients | 56 | 219 | — |
| Age, y | |||
| >60 | 10 (17.9) | 117 (53.4) | <.0001 |
| ≤60 | 46 (82.1) | 102 (46.6) | |
| Sex | |||
| Female | 16 (28.6) | 86 (39.3) | .1391 |
| Male | 40 (71.4) | 133 (60.1) | |
| Performance status† | |||
| 0-1 | 41 (73.2) | 176 (81.9) | .1491 |
| 2-4 | 15 (26.8) | 39 (18.1) | |
| Elevated LDH† | |||
| Yes | 32 (59.3) | 97 (46.4) | .0922 |
| No | 22 (40.7) | 112 (53.6) | |
| Subtype† | |||
| GCB | 21 (37.5) | 83 (38.1) | .9372 |
| Non-GCB | 35 (62.5) | 135 (61.9) | |
| Stage† | |||
| I-II | 14 (25.9) | 112 (54.6) | .0002 |
| III-IV | 40 (74.1) | 93 (45.4) | |
| IPI† | |||
| 0-2 | 28 (51.9) | 146 (71.2) | .0070 |
| 3-5 | 26 (48.1) | 59 (28.8) | |
| Spleen involvement† | |||
| Yes | 19 (38.0) | 34 (17.6) | .0019 |
| No | 31 (62.0) | 159 (82.4) | |
| Liver involvement† | |||
| Yes | 7 (14.0) | 14 (7.3) | .1303 |
| No | 43 (86.0) | 179 (92.7) |
| . | HBsAg+ DLBCL . | HBsAg− DLBCL . | P* . |
|---|---|---|---|
| No. of patients | 56 | 219 | — |
| Age, y | |||
| >60 | 10 (17.9) | 117 (53.4) | <.0001 |
| ≤60 | 46 (82.1) | 102 (46.6) | |
| Sex | |||
| Female | 16 (28.6) | 86 (39.3) | .1391 |
| Male | 40 (71.4) | 133 (60.1) | |
| Performance status† | |||
| 0-1 | 41 (73.2) | 176 (81.9) | .1491 |
| 2-4 | 15 (26.8) | 39 (18.1) | |
| Elevated LDH† | |||
| Yes | 32 (59.3) | 97 (46.4) | .0922 |
| No | 22 (40.7) | 112 (53.6) | |
| Subtype† | |||
| GCB | 21 (37.5) | 83 (38.1) | .9372 |
| Non-GCB | 35 (62.5) | 135 (61.9) | |
| Stage† | |||
| I-II | 14 (25.9) | 112 (54.6) | .0002 |
| III-IV | 40 (74.1) | 93 (45.4) | |
| IPI† | |||
| 0-2 | 28 (51.9) | 146 (71.2) | .0070 |
| 3-5 | 26 (48.1) | 59 (28.8) | |
| Spleen involvement† | |||
| Yes | 19 (38.0) | 34 (17.6) | .0019 |
| No | 31 (62.0) | 159 (82.4) | |
| Liver involvement† | |||
| Yes | 7 (14.0) | 14 (7.3) | .1303 |
| No | 43 (86.0) | 179 (92.7) |
Values are reported as n (%) of patients unless indicated otherwise.
IPI, international prognostic index; LDH, lactate dehydrogenase.
χ2 test was used for comparison. Significant values (P < .05) are highlighted in bold.
The calculation was based on 271, 263, 274, 259, or 243 samples with available data.